The Investigation of the Effect of a Dandelion Herbal Capsule (GHASEDAK Capsule) on Fibrosis and Liver Function in NAFLD: A Randomized, Double Blind, Placebo-controlled, Single-center Clinical Trial

Introduction: Non-alcoholic fatty liver disease (NAFLD) is a major health prob-lem with a high incidence rate. Dandelion (Taraxacum peregrinum), a member of the Aster-aceae family, is widely used in traditional medicine for its therapeutic properties. This study aimed to evaluate the effect of GHASEDAK dandelion herbal capsules on liver fibrosis and function in patients with NAFLD. Methods: This was a randomized, double-blind, placebo-controlled, single-center clinical trial. 50 eligible patients (25 per group) with grade 2 or 3 NAFLD (confirmed by laboratory tests and ultrasound) were randomized to receive either 300 mg dandelion capsules (900 mg/day; 3 capsules) or a matching placebo for 12 weeks, alongside lifestyle manner. Liver fibrosis (FibroScan®) and liver enzyme levels were assessed at baseline and after the inter-vention. Data were analyzed using t-tests and chi-square tests. Results: In the dandelion group, mean liver fibrosis decreased from 6.97±1.57 to 5.87±1.36 (P< 0.0001). Alanine aminotransferase (ALT) decreased from 62.52±21.24 to 41.92±12.35, and aspartate aminotransferase (AST) from 46.68±18.01 to 28.24±8.07 (both P< 0.0001). Conclusion: Daily consumption of 900 mg of dandelion capsules, combined with lifestyle modification, significantly reduced liver fibrosis and serum liver enzyme levels in patients with NAFLD compared with the control group.